Contributions
Abstract: EP1352
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Epidemiology
Introduction: The stigma associated with neurological disorders contributes to poor health-related quality of life outcomes. Understanding stigma in multiple sclerosis (MS) may be important to carry out specific education intervention strategies. However, limited information is available in people with primary progressive multiple sclerosis (PPMS).
Objective: To assess the perception of stigma and its impact in PPMS.
Methods: A multicenter, cross-sectional study was conducted in a sample of adult patients with PPMS (McDonald 2010 criteria). The 8-item Stigma Scale for Chronic Illness (SSCI-8), the 29-item Multiple Sclerosis Impact Scale (MSIS-29), and the Beck Depression Inventory-Fast Screen (BDI-FS) were used to gather information on stigma, health-related quality of life and depressive symptoms, respectively.
Results: Fifty-five subjects were studied (mean age 55.8 ± 9.5 years, 56.4% male). The mean time since MS diagnosis was 4.1 ± 4.5 years and the median Expanded Disability Status Scale (EDSS) score was 5.5 (interquartile range 4.0, 6.5). Stigma prevalence was 78.2% (n=43). Twenty-four subjects (43.6%) were classified as depressed and six (11%) had a moderate-to-severe depression. SSCI-8 score correlated with physical (rho=0.464, p< 0.001) and psychological (rho=0.358, p=0.007) MSIS-29 subscores. Stigma predicted concurrent depression (OR=1.135; 95%CI: 1.002-1.286; p=0.046).
Conclusion: Stigma is highly prevalent in people with PPMS with a detrimental effect on their quality of life and mood.
Disclosure: This study was funded by the Medical Department of Roche Farma Spain. D.P. and J.M. are employees of Roche Farma Spain. The rest of the authors declare no potential conflict of interest.
Abstract: EP1352
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Epidemiology
Introduction: The stigma associated with neurological disorders contributes to poor health-related quality of life outcomes. Understanding stigma in multiple sclerosis (MS) may be important to carry out specific education intervention strategies. However, limited information is available in people with primary progressive multiple sclerosis (PPMS).
Objective: To assess the perception of stigma and its impact in PPMS.
Methods: A multicenter, cross-sectional study was conducted in a sample of adult patients with PPMS (McDonald 2010 criteria). The 8-item Stigma Scale for Chronic Illness (SSCI-8), the 29-item Multiple Sclerosis Impact Scale (MSIS-29), and the Beck Depression Inventory-Fast Screen (BDI-FS) were used to gather information on stigma, health-related quality of life and depressive symptoms, respectively.
Results: Fifty-five subjects were studied (mean age 55.8 ± 9.5 years, 56.4% male). The mean time since MS diagnosis was 4.1 ± 4.5 years and the median Expanded Disability Status Scale (EDSS) score was 5.5 (interquartile range 4.0, 6.5). Stigma prevalence was 78.2% (n=43). Twenty-four subjects (43.6%) were classified as depressed and six (11%) had a moderate-to-severe depression. SSCI-8 score correlated with physical (rho=0.464, p< 0.001) and psychological (rho=0.358, p=0.007) MSIS-29 subscores. Stigma predicted concurrent depression (OR=1.135; 95%CI: 1.002-1.286; p=0.046).
Conclusion: Stigma is highly prevalent in people with PPMS with a detrimental effect on their quality of life and mood.
Disclosure: This study was funded by the Medical Department of Roche Farma Spain. D.P. and J.M. are employees of Roche Farma Spain. The rest of the authors declare no potential conflict of interest.